title: Concurrent chemoradiotherapy with cisplatin and docetaxel for advanced head and neck cancer. A phase I study.
abstract: BACKGROUND
  This phase I study of weekly low-dose administration of cisplatin (CDDP) and docetaxel (DOC) combined with concurrent conventionally fractionated radiotherapy was designed for locoregionally advanced head and neck cancer.
  
  
  METHODS
  Twelve patients were treated at varying levels of DOC (level 1: 5 mg/m2/week, level 2: 7.5 mg/m2/week, level 3: 10 mg/m2/week) with CDDP constant at 20 mg/m2/week in four cohorts of three patients. Radiation was given at 1.8-2.0 Gy/fraction to a total dose of 60-70.2 Gy.
  
  
  RESULTS
  Hematological toxicities, except lymphocytopenia, were minimal. Mucosal toxicities, especially grade 3 mucositis, were common. Dose-limiting toxicity was grade 3 pain, although level 3 did not reach a maximum tolerated dose. No grade 4 toxicities were observed. Complete response rate ranged from 33% to 67% in the various dose levels.
  
  
  CONCLUSIONS
  This concurrent chemoradiotherapy seems to be a promising treatment modality, in which level 3 is the recommended dose for a phase II study.
authors.affiliation: Department of Otolaryngology and Sensory Organ Surgery Osaka University Graduate School of Medicine, 2-2 Yamadaoka, Suita, Osaka 565-0871, Japan. hinohara@ent.med.osaka-u.ac.jp
authors.forename: Hidenori
authors.initials: H
authors.lastname: Inohara
authors.forename: Takehiro
authors.initials: T
authors.lastname: Inoue
authors.forename: Shiro
authors.initials: S
authors.lastname: Akahani
authors.forename: Yoshifumi
authors.initials: Y
authors.lastname: Yamamoto
authors.forename: Yukinori
authors.initials: Y
authors.lastname: Takenaka
authors.forename: Takashi
authors.initials: T
authors.lastname: Nakagawa
authors.forename: Fumiaki
authors.initials: F
authors.lastname: Isohashi
authors.forename: Takeshi
authors.initials: T
authors.lastname: Kubo
mesh_terms: D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D002277:Carcinoma / Q000188:drug therapy / Q000532:radiotherapy; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy / Q000532:radiotherapy; D002945:Cisplatin / Q000008:administration & dosage / Q000009:adverse effects; D003131:Combined Modality Therapy; D000077143:Docetaxel; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D005260:Female; D006258:Head and Neck Neoplasms / Q000188:drug therapy* / Q000532:radiotherapy*; D006801:Humans; D008297:Male; D008875:Middle Aged; D043823:Taxoids / Q000008:administration & dosage / Q000009:adverse effects
chemical_list: D043823:Taxoids; D000077143:Docetaxel; D002945:Cisplatin